# BMY catalysts: BRISTOL MYERS SQUIBB CO PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bmy/catalysts

> BRISTOL MYERS SQUIBB CO (BMY) has 130 upcoming catalysts. The next is the Sotyktu (deucravacitinib) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | BRISTOL MYERS SQUIBB CO |
| Ticker | BMY (NYSE) |
| SEC CIK | 14272 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/bmy |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 17, 2012 | [Farxiga (dapagliflozin) complete response letter (CRL)](https://sec-api.dev/pdufa/dapagliflozin) | BMY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA202293_20120117.pdf%22)) |
| August 1, 2017 | [Idhifa (enasidenib mesylate) FDA approval](https://sec-api.dev/pdufa/enasidenib) | BMY |  | completed, approved | "NDA209606 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170801, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product IDHIFA (ENASIDENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209606%22)) |
| August 16, 2019 | [Inrebic (fedratinib hydrochloride) FDA approval](https://sec-api.dev/pdufa/fedratinib) | BMY |  | completed, approved | "NDA212327 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190816, review_priority PRIORITY; sponsor_name BRISTOL-MYERS; product INREBIC (FEDRATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212327%22)) |
| November 8, 2019 | [Reblozyl (luspatercept-aamt) FDA approval](https://sec-api.dev/pdufa/luspatercept-aamt) | BMY |  | completed, approved | "BLA761136 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191108, review_priority PRIORITY; sponsor_name CELGENE CORP; product REBLOZYL (LUSPATERCEPT-AAMT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761136%22)) |
| March 10, 2020 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-108 (Efficacy): submission_status AP, submission_status_date 20200310, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| March 10, 2020 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-78 (Efficacy): submission_status AP, submission_status_date 20200310, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| March 25, 2020 | [Zeposia (ozanimod hydrochloride) FDA approval](https://sec-api.dev/pdufa/ozanimod) | BMY |  | completed, approved | "NDA209899 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200325, review_priority STANDARD; sponsor_name BRISTOL; product ZEPOSIA (OZANIMOD HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209899%22)) |
| April 3, 2020 | [Reblozyl (luspatercept-aamt) FDA approval](https://sec-api.dev/pdufa/luspatercept-aamt) | BMY |  | completed, approved | "BLA761136 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20200403, review_priority STANDARD; sponsor_name CELGENE CORP; product REBLOZYL (LUSPATERCEPT-AAMT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761136%22)) |
| May 14, 2020 | [Pomalyst (pomalidomide) label expansion decision](https://sec-api.dev/pdufa/pomalidomide) | BMY |  | completed, approved | "NDA204026 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20200514, review_priority PRIORITY; sponsor_name BRISTOL; product POMALYST (POMALIDOMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204026%22)) |
| May 15, 2020 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-109 (Efficacy): submission_status AP, submission_status_date 20200515, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 15, 2020 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-80 (Efficacy): submission_status AP, submission_status_date 20200515, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| May 26, 2020 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-110 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 26, 2020 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-82 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| June 10, 2020 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-81 (Efficacy): submission_status AP, submission_status_date 20200610, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| July 31, 2020 | [Evotaz (atazanavir sulfate; cobicistat) label expansion decision](https://sec-api.dev/pdufa/atazanavir-cobicistat) | BMY |  | completed, approved | "NDA206353 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20200731, review_priority STANDARD; sponsor_name BRISTOL; product EVOTAZ (ATAZANAVIR SULFATE; COBICISTAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206353%22)) |
| September 1, 2020 | [ONUREG (azacitidine) FDA approval](https://sec-api.dev/pdufa/azacitidine) | BMY |  | completed, approved | "NDA214120 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200901, review_priority PRIORITY; sponsor_name BRISTOL; product ONUREG (AZACITIDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214120%22)) |
| September 18, 2020 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-112 (Efficacy): submission_status AP, submission_status_date 20200918, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| September 18, 2020 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-85 (Efficacy): submission_status AP, submission_status_date 20200918, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| October 2, 2020 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-115 (Efficacy): submission_status AP, submission_status_date 20201002, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| October 2, 2020 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-89 (Efficacy): submission_status AP, submission_status_date 20201002, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| November 20, 2020 | [Pomalyst (pomalidomide) label expansion decision](https://sec-api.dev/pdufa/pomalidomide) | BMY |  | completed, approved | "NDA204026 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20201120, review_priority PRIORITY; sponsor_name BRISTOL; product POMALYST (POMALIDOMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204026%22)) |
| November 24, 2020 | [Idhifa (enasidenib mesylate) label expansion decision](https://sec-api.dev/pdufa/enasidenib) | BMY |  | completed, approved | "NDA209606 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20201124, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product IDHIFA (ENASIDENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209606%22)) |
| January 22, 2021 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-90 (Efficacy): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| April 16, 2021 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-91 (Efficacy): submission_status AP, submission_status_date 20210416, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| May 20, 2021 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-92 (Efficacy): submission_status AP, submission_status_date 20210520, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| May 25, 2021 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-121 (Efficacy): submission_status AP, submission_status_date 20210525, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 27, 2021 | [Zeposia (ozanimod hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ozanimod) | BMY |  | completed, approved | "NDA209899 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20210527, review_priority PRIORITY; sponsor_name BRISTOL; product ZEPOSIA (OZANIMOD HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209899%22)) |
| July 15, 2021 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-99 (Efficacy): submission_status AP, submission_status_date 20210715, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| July 30, 2021 | [Romidepsin (romidepsin) label expansion decision](https://sec-api.dev/pdufa/romidepsin) | BMY |  | completed, approved | "NDA022393 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20210730, review_priority STANDARD; sponsor_name BRISTOL-MYERS; product ISTODAX (ROMIDEPSIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022393%22)) |
| August 19, 2021 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20210819, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| December 15, 2021 | [Orencia (abatacept) label expansion decision](https://sec-api.dev/pdufa/abatacept) | BMY |  | completed, approved | "BLA125118 SUPPL-240 (Efficacy): submission_status AP, submission_status_date 20211215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product ORENCIA (ABATACEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125118%22)) |
| March 4, 2022 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-112 (Efficacy): submission_status AP, submission_status_date 20220304, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| March 18, 2022 | [Opdualag (nivolumab; relatlimab-rmbw) FDA approval](https://sec-api.dev/pdufa/nivolumab-relatlimab-rmbw) | BMY | To treat unresectable or metastatic melanoma | completed, approved | "Opdualag \| nivolumab and relatlimab-rmbw \| 3/18/2022 \| To treat unresectable or metastatic melanomaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| March 22, 2022 | [Empliciti (elotuzumab) label expansion decision](https://sec-api.dev/pdufa/elotuzumab) | BMY |  | completed, approved | "BLA761035 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20220322, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product EMPLICITI (ELOTUZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761035%22)) |
| April 28, 2022 | [Camzyos® (mavacamten) FDA approval](https://sec-api.dev/pdufa/mavacamten) | BMY | To treat certain classes of obstructive hypertrophic cardiomyopathy | completed, approved | "Camzyos \| mavacamten \| 4/28/2022 \| To treat certain classes of obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| May 11, 2022 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-124 (Efficacy): submission_status AP, submission_status_date 20220511, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 11, 2022 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-108 (Efficacy): submission_status AP, submission_status_date 20220511, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| May 20, 2022 | [ONUREG (azacitidine) label expansion decision](https://sec-api.dev/pdufa/azacitidine) | BMY |  | completed, approved | "NDA050794 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20220520, review_priority PRIORITY; sponsor_name BRISTOL-MYERS; product VIDAZA (AZACITIDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA050794%22)) |
| May 27, 2022 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-122 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 27, 2022 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-105 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| July 14, 2022 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-114 (Efficacy): submission_status AP, submission_status_date 20220714, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| September 9, 2022 | [Sotyktu (deucravacitinib) FDA approval](https://sec-api.dev/pdufa/deucravacitinib) | BMY | To treat moderate-to-severe plaque psoriasis | completed, approved | "Sotyktu \| deucravacitinib \| 9/9/2022 \| To treat moderate-to-severe plaque psoriasisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| December 12, 2022 | [Krazati (adagrasib) FDA approval](https://sec-api.dev/pdufa/adagrasib) | BMY |  | completed, approved | "Krazati \| adagrasib \| 12/12/2022 \| To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| February 15, 2023 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-129 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| February 15, 2023 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-119 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| June 15, 2023 | [Camzyos® (mavacamten) label expansion decision](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed, approved | "NDA214998 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230615, review_priority STANDARD; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22)) |
| August 28, 2023 | [Reblozyl (luspatercept-aamt) label expansion decision](https://sec-api.dev/pdufa/luspatercept-aamt) | BMY |  | completed, approved | "BLA761136 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20230828, review_priority PRIORITY; sponsor_name CELGENE CORP; product REBLOZYL (LUSPATERCEPT-AAMT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761136%22)) |
| October 13, 2023 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-121 (Efficacy): submission_status AP, submission_status_date 20231013, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| October 30, 2023 | [Orencia (abatacept) label expansion decision](https://sec-api.dev/pdufa/abatacept) | BMY |  | completed, approved | "BLA125118 SUPPL-250 (Efficacy): submission_status AP, submission_status_date 20231030, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product ORENCIA (ABATACEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125118%22)) |
| November 15, 2023 | [AUGTYRO (repotrectinib) FDA approval](https://sec-api.dev/pdufa/repotrectinib) | BMY | To treat ROS1-positive non-small cell lung cancer | completed, approved | "Augtyro \| repotrectinib \| 11/15/2023 \| To treat ROS1-positive non-small cell lung cancerDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| January 26, 2024 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-122 (Efficacy): submission_status AP, submission_status_date 20240126, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| March 6, 2024 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-125 (Efficacy): submission_status AP, submission_status_date 20240306, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| March 15, 2024 | [ABECMA (idecabtagene vicleucel) FDA advisory committee meeting](https://sec-api.dev/pdufa/idecabtagene-vicleucel) | BMY |  | completed, positive | "During the afternoon session, the Committee will discuss sBLA 125736.218 for ABECMA (idecabtagene vicleucel), suspension for intravenous infusion, submitted by Celgene Corp., a Bristol-Myers Squibb Co. The proposed indication is for the treatment of adult patients with relapsed or refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-15-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03152024)) |
| June 13, 2024 | [AUGTYRO (repotrectinib) label expansion decision](https://sec-api.dev/pdufa/repotrectinib) | BMY |  | completed, approved | "NDA218213 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20240613, review_priority PRIORITY; sponsor_name BRISTOL; product AUGTYRO (REPOTRECTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218213%22)) |
| June 21, 2024 | [Krazati (adagrasib) label expansion decision](https://sec-api.dev/pdufa/adagrasib) | BMY |  | completed, approved | "NDA216340 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority PRIORITY; sponsor_name BRISTOL; product KRAZATI (ADAGRASIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216340%22)) |
| August 30, 2024 | [Zeposia (ozanimod hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ozanimod) | BMY |  | completed, approved | "NDA209899 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240830, review_priority STANDARD; sponsor_name BRISTOL; product ZEPOSIA (OZANIMOD HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209899%22)) |
| September 26, 2024 | [Yervoy® (ipilimumab) FDA advisory committee meeting](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed | "The Committee will discuss the existing sBLAs which were approved for patients with previously untreated unresectable or metastatic esophageal squamous cell carcinoma: sBLA 125514/S-096 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; sBLAs 125554/S-105 and S-106 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co.; and sBLA 125377/S-122 for YERVOY (ipilimumab) injection, submitted by Bristol Myers-Squibb Co." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024)) |
| September 26, 2024 | [Opdivo® (nivolumab) FDA advisory committee meeting](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed | "The Committee will discuss the existing supplemental biologics license applications (sBLA) which were approved for patients with previously untreated HER2-negative unresectable or metastatic gastric or gastroesophageal adenocarcinoma: sBLA 125554/S-091 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co. and sBLA 125514/S-143 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024)) |
| September 26, 2024 | [Cobenfy (trospium chloride; xanomeline tartrate) FDA approval](https://sec-api.dev/pdufa/trospium-xanomeline) | BMY | To treat schizophreniaPress Release | completed, approved | "Cobenfy \| xanomeline and trospium chloride \| 9/26/2024 \| To treat schizophreniaPress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| October 3, 2024 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-127 (Efficacy): submission_status AP, submission_status_date 20241003, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| December 27, 2024 | [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) FDA approval](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab) | BMY |  | completed, approved | "BLA761381 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20241227, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22)) |
| January 28, 2025 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| February 6, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000037/a2024ex991-filing.htm)) |
| April 8, 2025 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20250408, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| April 8, 2025 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20250408, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| April 17, 2025 | [Eliquis (apixaban) FDA approval](https://sec-api.dev/pdufa/apixaban) | BMY |  | completed, approved | "NDA220073 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250417, review_priority PRIORITY; sponsor_name BRISTOL; product ELIQUIS (APIXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220073%22)) |
| April 17, 2025 | [Eliquis (apixaban) label expansion decision](https://sec-api.dev/pdufa/apixaban) | BMY |  | completed, approved | "NDA202155 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product ELIQUIS (APIXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202155%22)) |
| April 17, 2025 | [Camzyos® (mavacamten) label expansion decision](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed, approved | "NDA214998 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22)) |
| April 21, 2025 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA assigned a PDUFA goal date of April 21, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) |
| April 24, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports First Quarter Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000089/a2025q1ex991-filing.htm)) |
| May 15, 2025 | [Zeposia (ozanimod hydrochloride) primary completion](https://sec-api.dev/pdufa/ozanimod) | BMY | Multiple Sclerosis | withdrawn | "NCT04140305 (Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04140305)) |
| May 22, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Extensive-stage Small Cell Lung Cancer | completed | "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04702880)) |
| May 23, 2025 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-136 (Efficacy): submission_status AP, submission_status_date 20250523, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| May 23, 2025 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-133 (Efficacy): submission_status AP, submission_status_date 20250523, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| May 26, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis | completed | "NCT04717414 (An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-26 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04717414)) |
| June 23, 2025 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "This approval, granted more than two months ahead of the June 23, 2025 PDUFA goal date, follows the FDA's prior decision to grant the application Breakthrough Therapy Designation and Priority Review status." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm)) |
| July 14, 2025 | [Lonsurf primary completion](https://sec-api.dev/pdufa/lonsurf) | BMY | Colorectal Neoplasms | withdrawn | "NCT05328908 (A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05328908)) |
| July 29, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Clear Cell Renal Cell Carcinoma | completed | "NCT04810078 (A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-09-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04810078)) |
| July 31, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Second Quarter Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000129/a2025q2ex991-filing.htm)) |
| August 1, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Beta-thalassemia | completed | "NCT05567458 (A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05567458)) |
| August 4, 2025 | [RHUPH20 primary completion](https://sec-api.dev/pdufa/rhuph20) | BMY | Melanoma | completed | "NCT05625399 (A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05625399)) |
| August 11, 2025 | [ABECMA (idecabtagene vicleucel) primary completion](https://sec-api.dev/pdufa/idecabtagene-vicleucel) | BMY | Multiple Myeloma | completed | "NCT06045806 (A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-11 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045806)) |
| August 14, 2025 | [Cendakimab primary completion](https://sec-api.dev/pdufa/cendakimab) | BMY | Eosinophilic Esophagitis | completed | "NCT04991935 (Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-04-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04991935)) |
| September 30, 2025 | [Zeposia (ozanimod hydrochloride) primary completion](https://sec-api.dev/pdufa/ozanimod) | BMY | Colitis, Ulcerative | completed | "NCT03915769 (To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03915769)) |
| October 1, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | completed | "NCT06045689 (A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045689)) |
| October 27, 2025 | [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) label expansion decision](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab) | BMY |  | completed, approved | "BLA761381 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20251027, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22)) |
| October 30, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Third Quarter Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/a2025q3ex991.htm)) |
| October 31, 2025 | [ONUREG (azacitidine) primary completion](https://sec-api.dev/pdufa/azacitidine) | BMY | Leukemia, Myeloid, Acute | completed | "NCT05413018 (An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05413018)) |
| November 12, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Mesothelioma, Malignant | completed | "NCT05136677 (A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05136677)) |
| November 24, 2025 | [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) label expansion decision](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab) | BMY |  | completed, approved | "BLA761381 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251124, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22)) |
| November 25, 2025 | [Camzyos® (mavacamten) primary completion](https://sec-api.dev/pdufa/mavacamten) | BMY | Cardiomyopathy, Hypertrophic | completed | "NCT06253221 (A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06253221)) |
| December 5, 2025 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act goal date of December 5, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/a2025q3ex991.htm)) |
| January 15, 2026 | [BB2121 primary completion](https://sec-api.dev/pdufa/bb2121) | BMY | Multiple Myeloma | completed | "NCT03601078 (An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-15 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03601078)) |
| January 16, 2026 | [Camzyos® (mavacamten) primary completion](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed | "NCT03723655 (A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03723655)) |
| January 16, 2026 | [MRTX849 primary completion](https://sec-api.dev/pdufa/mrtx849) | BMY | Advanced Colorectal Cancer; Metastatic Colorectal Cancer | completed | "NCT04793958 (Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04793958)) |
| February 5, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000002/a2025q4ex991.htm)) |
| February 16, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer | completed | "NCT03661320 (A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-16 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03661320)) |
| February 23, 2026 | [Empliciti (elotuzumab) primary completion](https://sec-api.dev/pdufa/elotuzumab) | BMY | Multiple Myeloma | completed | "NCT02719613 (Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02719613)) |
| March 6, 2026 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA assigned PDUFA goal date of March 6, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm)) |
| March 6, 2026 | [Sotyktu (deucravacitinib) label expansion decision](https://sec-api.dev/pdufa/deucravacitinib) | BMY |  | completed, approved | "NDA214958 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name BRISTOL; product SOTYKTU (DEUCRAVACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214958%22)) |
| March 20, 2026 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20260320, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| March 25, 2026 | [Xanomeline and trospium chloride capsules primary completion](https://sec-api.dev/pdufa/xanomeline-and-trospium) | BMY | Schizophrenia | completed | "NCT05304767 (An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05304767)) |
| April 6, 2026 | [Cendakimab topline data readout](https://sec-api.dev/pdufa/cendakimab) | BMY | Eosinophilic Esophagitis | completed | "NCT04991935 (Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-04-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04991935?tab=results)) |
| April 8, 2026 | [Doxorubicin PDUFA date](https://sec-api.dev/pdufa/doxorubicin) | BMY |  | scheduled | "The FDA assigned a PDUFA goal date of April 8, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm)) |
| April 9, 2026 | [ONUREG (azacitidine) label expansion decision](https://sec-api.dev/pdufa/azacitidine) | BMY |  | completed, approved | "NDA214120 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260409, review_priority STANDARD; sponsor_name BRISTOL; product ONUREG (AZACITIDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214120%22)) |
| April 13, 2026 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Multiple Myeloma | completed | "NCT03651128 (Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-13 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03651128)) |
| April 30, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports First Quarter Financial Results for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/a2026q1ex991.htm)) |
| May 27, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Hepatocellular Carcinoma; Liver Cancer | completed | "NCT03383458 (A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03383458)) |
| June 17, 2026 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Extensive-stage Small Cell Lung Cancer | completed | "NCT04702880 (A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04702880?tab=results)) |
| June 19, 2026 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Lymphoma, Follicular | completed | "NCT06425302 (A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06425302)) |
| July 9, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Hepatocellular Carcinoma | completed | "NCT04039607 (A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-09 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04039607)) |
| July 16, 2026 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY | Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis | completed | "NCT04717414 (An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-26 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04717414?tab=results)) |
| July 21, 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Psoriasis | completed | "NCT04036435 (Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04036435)) |
| July 30, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |
| July 31, 2026 | [Arlocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) | BMY | Multiple Myeloma | completed | "NCT06297226 (Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-07-31 (ACTUAL); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297226)) |
| August 13, 2026 | [Zenbexus (iberdomide hydrochloride) FDA approval](https://sec-api.dev/pdufa/iberdomide) | BMY |  | completed, approved | "Zenbexus \| iberdomide \| 8/13/2026 \| To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 17, 2026 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA assigned a Prescription Drug User Fee Act date of August 17, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/a2026q1ex991.htm)) |
| August 26, 2026 | [RHUPH20 topline data readout](https://sec-api.dev/pdufa/rhuph20) | BMY | Melanoma | completed | "NCT05625399 (A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05625399?tab=results)) |
| Sep to Dec 2026 | [Mezigdomide topline data readout](https://sec-api.dev/pdufa/mezigdomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05552976)) |
| Sep to Dec 2026 | [Adagrasib oral dose of 400 mg twice daily tablets topline data readout](https://sec-api.dev/pdufa/adagrasib-oral-dose-of) | BMY | Advanced NSCLC; Metastatic Lung Cancer | scheduled | "NCT05609578 (Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609578)) |
| September 22, 2026 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Clear Cell Renal Cell Carcinoma | completed | "NCT04810078 (A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-09-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04810078?tab=results)) |
| September 2026 | [Mezigdomide primary completion](https://sec-api.dev/pdufa/mezigdomide) | BMY | Relapsed or Refractory Multiple Myeloma | delayed | "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05552976)) |
| September 30, 2026 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA has granted the application Priority Review and assigned a PDUFA date of September 30, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm)) |
| September 30, 2026 | [Camzyos® (mavacamten) label expansion decision](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed, approved | "NDA214998 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260930, review_priority PRIORITY; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22)) |
| September 2026 | [Adagrasib oral dose of 400 mg twice daily tablets primary completion](https://sec-api.dev/pdufa/adagrasib-oral-dose-of) | BMY | Advanced NSCLC; Metastatic Lung Cancer | delayed | "NCT05609578 (Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609578)) |
| Oct 2026 | [Brengitecan interim data readout](https://sec-api.dev/pdufa/brengitecan) | BMY | unresectable locally advanced, recurrent or metastatic hormone receptor-positive | scheduled | "Product Indication Date Developments izalontamab brengitecan (iza-bren) Breast Cancer October 2026 Announced, with SystImmune, that SystImmune's parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis of the randomized Phase III PANKU-Breast01 study, evaluating iza-bren, an investigational, potentially first-in-class, dual-targeting EGFRxHER3 bispecific antibody-drug conjugate (ADC), versus chemotherapy in patients with unresectable locally advanced, recurrent or metastatic hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer who have failed at least one prior line of chemotherapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm)) |
| Oct 2026 to Jan 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT05511363 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-10-05 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05511363)) |
| Oct 2026 to Jan 2027 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | scheduled | "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05617677)) |
| Oct 2026 to Jan 2027 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | scheduled | "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05620407)) |
| Oct 2026 to Jan 2027 | [Krazati (adagrasib) topline data readout](https://sec-api.dev/pdufa/adagrasib) | BMY | Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung | scheduled | "NCT05853575 (Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05853575)) |
| Oct 2026 to Jan 2027 | [Admilparant topline data readout](https://sec-api.dev/pdufa/admilparant) | BMY | Idiopathic Pulmonary Fibrosis | scheduled | "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003426)) |
| October 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | delayed | "NCT05511363 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-10-05 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05511363)) |
| October 2026 | [Admilparant primary completion](https://sec-api.dev/pdufa/admilparant) | BMY | Idiopathic Pulmonary Fibrosis | delayed | "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003426)) |
| October 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | delayed | "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05617677)) |
| October 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus | delayed | "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05620407)) |
| October 29, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/a2026q3ex991-filing.htm)) |
| October 2026 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung | delayed | "NCT05853575 (Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05853575)) |
| Nov 2026 to Feb 2027 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Sjögren's Syndrome | scheduled | "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05946941)) |
| Nov 2026 to Feb 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease | scheduled | "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585787)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar-I Disorder With Mania or Mania With Mixed Features | scheduled | "NCT06951698 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06951698)) |
| Nov 2026 to Feb 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar-I Disorder With Mania or Mania With Mixed Features | scheduled | "NCT06951698 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06951698)) |
| Nov 2026 to Feb 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar Disorder Type I With Mania or Mania With Mixed Features | scheduled | "NCT06951711 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06951711)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar Disorder Type I With Mania or Mania With Mixed Features | scheduled | "NCT06951711 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06951711)) |
| November 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Sjögren's Syndrome | scheduled | "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05946941)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease | scheduled | "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585787)) |
| Dec 2026 to Mar 2027 | [BMS-986435 topline data readout](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| Dec 2026 to Mar 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126224)) |
| Dec 2026 to Mar 2027 | [BMS-986446 topline data readout](https://sec-api.dev/pdufa/bms-986446) | BMY | Alzheimer Disease, Early Onset | scheduled | "NCT06268886 (Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268886)) |
| December 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126224)) |
| December 2026 | [BMS-986435 primary completion](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| December 2026 | [BMS-986446 primary completion](https://sec-api.dev/pdufa/bms-986446) | BMY | Alzheimer Disease, Early Onset | scheduled | "NCT06268886 (Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268886)) |
| Jan to Apr 2027 | [Pomalyst (pomalidomide) topline data readout](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519085)) |
| January 2027 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519085)) |
| Feb to May 2027 | [AUGTYRO (repotrectinib) topline data readout](https://sec-api.dev/pdufa/repotrectinib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06140836)) |
| Feb to May 2027 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946797)) |
| February 2027 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946797)) |
| February 2027 | [AUGTYRO (repotrectinib) primary completion](https://sec-api.dev/pdufa/repotrectinib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06140836 (A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06140836)) |
| Mar to Jun 2027 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Renal Cell Carcinoma | scheduled | "NCT03873402 (A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03873402)) |
| March 11, 2027 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |
| March 2027 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Renal Cell Carcinoma | scheduled | "NCT03873402 (A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03873402)) |
| May to Aug 2027 | [BMS-986368 topline data readout](https://sec-api.dev/pdufa/bms-986368) | BMY | Multiple Sclerosis Spasticity | scheduled | "NCT06782490 (A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-26 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06782490)) |
| May 13, 2027 | [Mezigdomide PDUFA date](https://sec-api.dev/pdufa/mezigdomide) | BMY | relapsed or refractory multiple myeloma | scheduled | "The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |
| May 2027 | [BMS-986368 primary completion](https://sec-api.dev/pdufa/bms-986368) | BMY | Multiple Sclerosis Spasticity | scheduled | "NCT06782490 (A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-26 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06782490)) |
| Jun to Sep 2027 | [Xanomeline/trospium chloride topline data readout](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Mania; Bipolar Disorder | scheduled | "NCT07140913 (A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07140913)) |
| June 2027 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Mania; Bipolar Disorder | scheduled | "NCT07140913 (A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07140913)) |
| Jul to Oct 2027 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY | Anemia | scheduled | "NCT05664737 (A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05664737)) |
| July 2027 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Anemia | scheduled | "NCT05664737 (A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05664737)) |
| Aug to Nov 2027 | [Golcadomide topline data readout](https://sec-api.dev/pdufa/golcadomide) | BMY | Large B-cell Lymphoma | scheduled | "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356129)) |
| Aug to Nov 2027 | [Bms-986489 (atigotatug+nivolumab) topline data readout](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab) | BMY | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06646276)) |
| August 2027 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Large B-cell Lymphoma | scheduled | "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356129)) |
| August 2027 | [Bms-986489 (atigotatug+nivolumab) primary completion](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab) | BMY | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06646276)) |
| Sep to Dec 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT05980949 (Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-07 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05980949)) |
| Sep to Dec 2027 | [BMS-986365 topline data readout](https://sec-api.dev/pdufa/bms-986365) | BMY | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764485)) |
| September 2027 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT05980949 (Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-07 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05980949)) |
| September 2027 | [BMS-986365 primary completion](https://sec-api.dev/pdufa/bms-986365) | BMY | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764485)) |
| Nov 2027 to Feb 2028 | [Zenbexus (iberdomide hydrochloride) topline data readout](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975997)) |
| Nov 2027 to Feb 2028 | [BMS-986368 topline data readout](https://sec-api.dev/pdufa/bms-986368) | BMY | Agitation; Alzheimer Disease | scheduled | "NCT06808984 (Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06808984)) |
| November 2027 | [Zenbexus (iberdomide hydrochloride) primary completion](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT04975997 (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975997)) |
| November 2027 | [BMS-986368 primary completion](https://sec-api.dev/pdufa/bms-986368) | BMY | Agitation; Alzheimer Disease | scheduled | "NCT06808984 (Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06808984)) |
| Dec 2027 to Mar 2028 | [BMS-986278 topline data readout](https://sec-api.dev/pdufa/bms-986278) | BMY | Progressive Pulmonary Fibrosis | scheduled | "NCT06025578 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-27 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06025578)) |
| Dec 2027 to Mar 2028 | [Pomalyst (pomalidomide) topline data readout](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma (RRMM) | scheduled | "NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06615479)) |
| December 2027 | [BMS-986278 primary completion](https://sec-api.dev/pdufa/bms-986278) | BMY | Progressive Pulmonary Fibrosis | scheduled | "NCT06025578 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-27 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06025578)) |
| December 2027 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma (RRMM) | scheduled | "NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06615479)) |
| Jan to Apr 2028 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY | Beta-Thalassemia | scheduled | "NCT04143724 (Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04143724)) |
| Jan to Apr 2028 | [TRUXIMA® (rituximab) topline data readout](https://sec-api.dev/pdufa/rituximab) | BMY | Lymphoma | scheduled | "NCT07015242 (A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-09 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015242)) |
| January 2028 | [TRUXIMA® (rituximab) primary completion](https://sec-api.dev/pdufa/rituximab) | BMY | Lymphoma | scheduled | "NCT07015242 (A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-09 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015242)) |
| January 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Beta-Thalassemia | scheduled | "NCT04143724 (Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04143724)) |
| Feb to May 2028 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease; Psychosis | scheduled | "NCT06947941 (A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-21 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947941)) |
| Feb to May 2028 | [Krazati (adagrasib) topline data readout](https://sec-api.dev/pdufa/adagrasib) | BMY | Solid Tumors | scheduled | "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415031)) |
| February 2028 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Solid Tumors | scheduled | "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415031)) |
| February 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease; Psychosis | scheduled | "NCT06947941 (A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-21 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947941)) |
| Mar to Jun 2028 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949684)) |
| Mar to Jun 2028 | [Iza-bren topline data readout](https://sec-api.dev/pdufa/iza-bren) | BMY | Breast Neoplasms | scheduled | "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926868)) |
| Mar to Jun 2028 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BMY | Early-Stage Non-Small Cell Lung Cancer | scheduled | "NCT07871214 (A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871214)) |
| March 2028 | [Iza-bren primary completion](https://sec-api.dev/pdufa/iza-bren) | BMY | Breast Neoplasms | scheduled | "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926868)) |
| March 2028 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BMY | Early-Stage Non-Small Cell Lung Cancer | scheduled | "NCT07871214 (A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871214)) |
| March 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949684)) |
| Apr to Jul 2028 | [Golcadomide topline data readout](https://sec-api.dev/pdufa/golcadomide) | BMY | Follicular Lymphoma | scheduled | "NCT06911502 (A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-24 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911502)) |
| April 2028 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Follicular Lymphoma | scheduled | "NCT06911502 (A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-24 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911502)) |
| May to Aug 2028 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY |  | scheduled | "NCT04064060 (A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04064060)) |
| May to Aug 2028 | [Zola-cel topline data readout](https://sec-api.dev/pdufa/zola-cel) | BMY | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT07015983 (A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015983)) |
| May 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY |  | scheduled | "NCT04064060 (A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04064060)) |
| May 2028 | [Zola-cel primary completion](https://sec-api.dev/pdufa/zola-cel) | BMY | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT07015983 (A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015983)) |
| Jun to Sep 2028 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar Disorder Type I With Mania | scheduled | "NCT06929273 (A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06929273)) |
| June 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Bipolar Disorder Type I With Mania | scheduled | "NCT06929273 (A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06929273)) |
| Jul to Oct 2028 | [Oral azacitidine topline data readout](https://sec-api.dev/pdufa/oral-azacitidine) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05469737 (A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05469737)) |
| July 2028 | [Oral azacitidine primary completion](https://sec-api.dev/pdufa/oral-azacitidine) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05469737 (A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05469737)) |
| Aug to Nov 2028 | [Navlimetostat topline data readout](https://sec-api.dev/pdufa/navlimetostat) | BMY | Solid Tumors | scheduled | "NCT07492680 (A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07492680)) |
| August 2028 | [Navlimetostat primary completion](https://sec-api.dev/pdufa/navlimetostat) | BMY | Solid Tumors | scheduled | "NCT07492680 (A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07492680)) |
| Sep to Dec 2028 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT06882785 (A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-23 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06882785)) |
| Sep to Dec 2028 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer's Disease | scheduled | "NCT06976203 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976203)) |
| Sep to Dec 2028 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer's Disease | scheduled | "NCT06976216 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976216)) |
| Sep to Dec 2028 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BMY |  | scheduled | "NCT07680764 (A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07680764)) |
| September 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer's Disease | scheduled | "NCT06976203 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976203)) |
| September 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer's Disease | scheduled | "NCT06976216 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976216)) |
| September 2028 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BMY |  | scheduled | "NCT07680764 (A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07680764)) |
| September 2028 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT06882785 (A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-23 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06882785)) |
| Oct 2028 to Jan 2029 | [Krazati (adagrasib) topline data readout](https://sec-api.dev/pdufa/adagrasib) | BMY | Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer | scheduled | "NCT04613596 (Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04613596)) |
| October 2028 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer | scheduled | "NCT04613596 (Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04613596)) |
| Nov 2028 to Feb 2029 | [Xanomeline/trospium chloride topline data readout](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Alzheimer Disease | scheduled | "NCT07011732 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011732)) |
| Nov 2028 to Feb 2029 | [Xanomeline/trospium chloride topline data readout](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Alzheimer's Disease | scheduled | "NCT07011745 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011745)) |
| Nov 2028 to Feb 2029 | [BMS-986353 topline data readout](https://sec-api.dev/pdufa/bms-986353) | BMY | Systemic Sclerosis | scheduled | "NCT07335562 (A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-11-14 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07335562)) |
| Nov 2028 to Feb 2029 | [Evifacotrep topline data readout](https://sec-api.dev/pdufa/evifacotrep) | BMY | Major Depressive Disorder | scheduled | "NCT07772531 (A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772531)) |
| November 2028 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Alzheimer's Disease | scheduled | "NCT07011745 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011745)) |
| November 2028 | [Evifacotrep primary completion](https://sec-api.dev/pdufa/evifacotrep) | BMY | Major Depressive Disorder | scheduled | "NCT07772531 (A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772531)) |
| November 2028 | [BMS-986353 primary completion](https://sec-api.dev/pdufa/bms-986353) | BMY | Systemic Sclerosis | scheduled | "NCT07335562 (A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-11-14 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07335562)) |
| November 2028 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Alzheimer Disease | scheduled | "NCT07011732 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011732)) |
| Dec 2028 to Mar 2029 | [Navlimetostat topline data readout](https://sec-api.dev/pdufa/navlimetostat) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06855771 (A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855771)) |
| Dec 2028 to Mar 2029 | [Iza-bren topline data readout](https://sec-api.dev/pdufa/iza-bren) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT07100080 (Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100080)) |
| December 2028 | [Iza-bren primary completion](https://sec-api.dev/pdufa/iza-bren) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT07100080 (Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100080)) |
| December 2028 | [Navlimetostat primary completion](https://sec-api.dev/pdufa/navlimetostat) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06855771 (A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855771)) |
| January 2029 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04772079)) |
| Jan to Apr 2029 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04772079)) |
| Jan to Apr 2029 | [Iza-bren topline data readout](https://sec-api.dev/pdufa/iza-bren) | BMY | Urothelial Cancer | scheduled | "NCT07106762 (Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07106762)) |
| January 2029 | [Iza-bren primary completion](https://sec-api.dev/pdufa/iza-bren) | BMY | Urothelial Cancer | scheduled | "NCT07106762 (Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-26 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07106762)) |
| Mar to Jun 2029 | [Zenbexus (iberdomide hydrochloride) topline data readout](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT05827016 (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05827016)) |
| Mar to Jun 2029 | [Xanomeline/trospium chloride topline data readout](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Schizophrenia | scheduled | "NCT07686263 (Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686263)) |
| March 2029 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Schizophrenia | scheduled | "NCT07686263 (Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686263)) |
| March 2029 | [Zenbexus (iberdomide hydrochloride) primary completion](https://sec-api.dev/pdufa/iberdomide) | BMY | Multiple Myeloma | scheduled | "NCT05827016 (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05827016)) |
| May to Aug 2029 | [Navlimetostat topline data readout](https://sec-api.dev/pdufa/navlimetostat) | BMY | Pancreatic Ductal Adenocarcinoma | scheduled | "NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076121)) |
| May 2029 | [Navlimetostat primary completion](https://sec-api.dev/pdufa/navlimetostat) | BMY | Pancreatic Ductal Adenocarcinoma | scheduled | "NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076121)) |
| Jun to Sep 2029 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease; Agitation | scheduled | "NCT06937229 (A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06937229)) |
| June 2029 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease; Agitation | scheduled | "NCT06937229 (A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06937229)) |
| Aug to Nov 2029 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Cancer | scheduled | "NCT03899155 (Pan Tumor Rollover Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-25 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03899155)) |
| Aug to Nov 2029 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT07284745 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284745)) |
| Aug to Nov 2029 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT07285798 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285798)) |
| August 2029 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT07284745 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284745)) |
| August 2029 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT07285798 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285798)) |
| August 2029 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Cancer | scheduled | "NCT03899155 (Pan Tumor Rollover Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-25 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03899155)) |
| Sep to Dec 2029 | [Krazati (adagrasib) topline data readout](https://sec-api.dev/pdufa/adagrasib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06875310 (A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06875310)) |
| September 2029 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06875310 (A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06875310)) |
| Oct 2029 to Jan 2030 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT06979453 (A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-12 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979453)) |
| October 2029 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Plaque Psoriasis | scheduled | "NCT06979453 (A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-12 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979453)) |
| Nov 2029 to Feb 2030 | [Admilparant topline data readout](https://sec-api.dev/pdufa/admilparant) | BMY | Pulmonary Fibrosis | scheduled | "NCT07441408 (Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441408)) |
| November 2029 | [Admilparant primary completion](https://sec-api.dev/pdufa/admilparant) | BMY | Pulmonary Fibrosis | scheduled | "NCT07441408 (Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441408)) |
| Dec 2029 to Mar 2030 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT07288567 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288567)) |
| December 2029 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia | scheduled | "NCT07288567 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288567)) |
| Feb to May 2030 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BMY | Untreated, Unresectable, or Metastatic Colorectal Cancer | scheduled | "NCT07221357 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221357)) |
| February 2030 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BMY | Untreated, Unresectable, or Metastatic Colorectal Cancer | scheduled | "NCT07221357 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-02-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221357)) |
| Mar to Jun 2030 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Juvenile Psoriatic Arthritis | scheduled | "NCT06869551 (A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06869551)) |
| Mar to Jun 2030 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia; Autism-Related Irritability | scheduled | "NCT07424404 (A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424404)) |
| March 2030 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Juvenile Psoriatic Arthritis | scheduled | "NCT06869551 (A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06869551)) |
| March 2030 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Schizophrenia; Autism-Related Irritability | scheduled | "NCT07424404 (A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424404)) |
| May to Aug 2030 | [Zolacabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/zolacabtagene-autoleucel) | BMY | Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia | scheduled | "NCT07603557 (Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-05-06 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07603557)) |
| May 2030 | [Zolacabtagene autoleucel primary completion](https://sec-api.dev/pdufa/zolacabtagene-autoleucel) | BMY | Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia | scheduled | "NCT07603557 (Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-05-06 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07603557)) |
| Jul to Oct 2030 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-small Cell Lung Cancer | scheduled | "NCT06561386 (A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-30 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06561386)) |
| July 2030 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-small Cell Lung Cancer | scheduled | "NCT06561386 (A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-30 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06561386)) |
| Sep to Dec 2030 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BMY | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07361497 (A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07361497)) |
| September 2030 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BMY | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07361497 (A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07361497)) |
| Oct 2030 to Jan 2031 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis | scheduled | "NCT07791199 (Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07791199)) |
| October 2030 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis | scheduled | "NCT07791199 (Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07791199)) |
| Nov 2030 to Feb 2031 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY |  | scheduled | "NCT07221149 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-11-08 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221149)) |
| November 2030 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY |  | scheduled | "NCT07221149 (A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-11-08 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221149)) |

## Drugs

- [Orencia (abatacept)](https://sec-api.dev/pdufa/abatacept): als and initiated a phase 2 trial
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib): Solid Tumors, Advanced Cancer, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- [Adagrasib oral dose of 400 mg twice daily tablets](https://sec-api.dev/pdufa/adagrasib-oral-dose-of): Advanced NSCLC
- [Admilparant](https://sec-api.dev/pdufa/admilparant): Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- [Eliquis (apixaban)](https://sec-api.dev/pdufa/apixaban): 
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel): Multiple Myeloma
- [Evotaz (atazanavir sulfate; cobicistat)](https://sec-api.dev/pdufa/atazanavir-cobicistat): 
- [ONUREG (azacitidine)](https://sec-api.dev/pdufa/azacitidine): acute myeloid leukemia, Leukemia, Myeloid, Acute
- [BB2121](https://sec-api.dev/pdufa/bb2121): Multiple Myeloma
- [BMS-986278](https://sec-api.dev/pdufa/bms-986278): Progressive Pulmonary Fibrosis
- [BMS-986353](https://sec-api.dev/pdufa/bms-986353): Systemic Sclerosis
- [BMS-986365](https://sec-api.dev/pdufa/bms-986365): Metastatic Castration-resistant Prostate Cancer
- [BMS-986368](https://sec-api.dev/pdufa/bms-986368): Agitation, Multiple Sclerosis Spasticity
- [BMS-986435](https://sec-api.dev/pdufa/bms-986435): Heart Failure
- [BMS-986446](https://sec-api.dev/pdufa/bms-986446): Alzheimer Disease, Early Onset
- [Bms-986489 (atigotatug+nivolumab)](https://sec-api.dev/pdufa/bms-986489-atigotatug-nivolumab): Extensive-Stage Small Cell Lung Cancer
- [Brengitecan](https://sec-api.dev/pdufa/brengitecan): unresectable locally advanced, recurrent or metastatic hormone receptor-positive
- [Cendakimab](https://sec-api.dev/pdufa/cendakimab): Eosinophilic Esophagitis
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib): To treat moderate-to-severe plaque psoriasis, Psoriasis, Systemic Lupus Erythematosus, Juvenile Psoriatic Arthritis, Sjögren's Syndrome, Plaque Psoriasis
- [Doxorubicin](https://sec-api.dev/pdufa/doxorubicin): 
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab): Multiple Myeloma
- [Idhifa (enasidenib mesylate)](https://sec-api.dev/pdufa/enasidenib): 
- [Evifacotrep](https://sec-api.dev/pdufa/evifacotrep): Major Depressive Disorder
- [Inrebic (fedratinib hydrochloride)](https://sec-api.dev/pdufa/fedratinib): 
- [Golcadomide](https://sec-api.dev/pdufa/golcadomide): Large B-cell Lymphoma, Follicular Lymphoma, Lymphoma, Follicular
- [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab)](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab): 
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide): Multiple Myeloma
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel): Multiple Myeloma
- [Yervoy® (ipilimumab)](https://sec-api.dev/pdufa/ipilimumab): 
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren): Urothelial Cancer, Breast Neoplasms, Non-Small Cell Lung Cancer
- [Karxt](https://sec-api.dev/pdufa/karxt): Psychosis Associated With Alzheimer's Disease, Schizophrenia, Irritability Associated With Autism Spectrum Disorder, Alzheimer's Disease, Bipolar-I Disorder With Mania or Mania With Mixed Features, Bipolar Disorder Type I With Mania, Alzheimer Disease, Bipolar Disorder Type I With Mania or Mania With Mixed Features
- [Lonsurf](https://sec-api.dev/pdufa/lonsurf): Colorectal Neoplasms
- [Luspatercept](https://sec-api.dev/pdufa/luspatercept): Myelodysplastic Syndromes (MDS), Anemia, Myelodysplastic Syndromes, Beta-thalassemia, Myeloproliferative Disorders
- [Reblozyl (luspatercept-aamt)](https://sec-api.dev/pdufa/luspatercept-aamt): 
- [Camzyos® (mavacamten)](https://sec-api.dev/pdufa/mavacamten): To treat certain classes of obstructive hypertrophic cardiomyopathy, Hypertrophic Cardiomyopathy, Cardiomyopathy, Hypertrophic
- [Mezigdomide](https://sec-api.dev/pdufa/mezigdomide): relapsed or refractory multiple myeloma
- [MRTX849](https://sec-api.dev/pdufa/mrtx849): Advanced Colorectal Cancer
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat): Carcinoma, Non-Small-Cell Lung, Solid Tumors, Pancreatic Ductal Adenocarcinoma
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab): advanced melanoma in patients, advanced melanoma, with unresectable advanced cutaneous melanoma, advanced melanoma in july 2025, treatment-na&iuml, Non-small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Mesothelioma, Malignant
- [Opdualag (nivolumab; relatlimab-rmbw)](https://sec-api.dev/pdufa/nivolumab-relatlimab-rmbw): To treat unresectable or metastatic melanoma
- [Oral azacitidine](https://sec-api.dev/pdufa/oral-azacitidine): Myelodysplastic Syndromes
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod): Multiple Sclerosis, Colitis, Ulcerative
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide): Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed or Refractory Multiple Myeloma
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig): locally advanced/metastatic triple-negative breast cancer, Untreated, Unresectable, or Metastatic Colorectal Cancer, Extensive-stage Small-cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Recurrent Glioblastoma
- [AUGTYRO (repotrectinib)](https://sec-api.dev/pdufa/repotrectinib): To treat ROS1-positive non-small cell lung cancer, Carcinoma, Non-Small-Cell Lung
- [RHUPH20](https://sec-api.dev/pdufa/rhuph20): Melanoma
- [TRUXIMA® (rituximab)](https://sec-api.dev/pdufa/rituximab): class iii or iv ln in august 2023, 2l relapsed/refractory dlbcl, class iii or class iv ln in august 2023, Lymphoma
- [Cobenfy (trospium chloride; xanomeline tartrate)](https://sec-api.dev/pdufa/trospium-xanomeline): To treat schizophreniaPress Release
- [Xanomeline and trospium chloride capsules](https://sec-api.dev/pdufa/xanomeline-and-trospium): Schizophrenia
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium): Schizophrenia, Alzheimer's Disease, Alzheimer Disease, Mania
- [Zola-cel](https://sec-api.dev/pdufa/zola-cel): Lupus Erythematosus, Systemic
- [Zolacabtagene autoleucel](https://sec-api.dev/pdufa/zolacabtagene-autoleucel): Chronic Immune Thrombocytopenia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bmy/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BMY catalysts: BRISTOL MYERS SQUIBB CO PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bmy/catalysts

```bibtex
@misc{secapidev_companies_bmy_catalysts_20261116,
  title        = {BMY catalysts: BRISTOL MYERS SQUIBB CO PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bmy/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bmy_catalysts_20261116","title":"BMY catalysts: BRISTOL MYERS SQUIBB CO PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bmy/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
